Bjørn O Eriksen Selected Research

Iohexol (Omnipaque)

1/2022	Serum matrix metalloproteinase 7 and accelerated glomerular filtration rate decline in a general non-diabetic population.
1/2022	Continuous Infusion of Iohexol to Monitor Perioperative Glomerular Filtration Rate.
1/2019	Correlation Between Baseline GFR and Subsequent Change in GFR in Norwegian Adults Without Diabetes and in Pima Indians.
1/2018	Office and Ambulatory Heart Rate as Predictors of Age-Related Kidney Function Decline.
2/2017	Blood pressure and age-related GFR decline in the general population.
2/2016	Residual Associations of Inflammatory Markers with eGFR after Accounting for Measured GFR in a Community-Based Cohort without CKD.
1/2016	Elevated blood pressure is not associated with accelerated glomerular filtration rate decline in the general non-diabetic middle-aged population.
7/2014	Subclinical cardiovascular disease is associated with a high glomerular filtration rate in the nondiabetic general population.
11/2012	Physical exercise, fasting glucose, and renal hyperfiltration in the general population: the Renal Iohexol Clearance Survey in Tromsø 6 (RENIS-T6).
8/2011	GFR normalized to total body water allows comparisons across genders and body sizes.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bjørn O Eriksen Research Topics

Disease

12	Cardiovascular Diseases (Cardiovascular Disease) 12/2022 - 12/2010
8	Kidney Diseases (Kidney Disease) 07/2022 - 12/2010
6	Albuminuria 12/2022 - 01/2007
4	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2018 - 01/2007
3	Ischemic Stroke 11/2018 - 07/2012
2	Chronic Renal Insufficiency 01/2021 - 01/2007
2	Renal Insufficiency (Renal Failure) 01/2021 - 01/2007
2	Diabetes Mellitus 01/2018 - 12/2010
1	Colorectal Neoplasms (Colorectal Cancer) 01/2022
1	Fibrosis (Cirrhosis) 01/2022
1	Inflammation (Inflammations) 08/2021
1	Hypertension (High Blood Pressure) 01/2021
1	Humeral Fractures 01/2021
1	Proteinuria 11/2020
1	Type 2 Diabetes Mellitus (MODY) 01/2019
1	Myocardial Infarction 11/2018
1	Isolated Systolic Hypertension 02/2017
1	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 01/2017
1	Hypertrophy 01/2017
1	Overweight 05/2016
1	Hyperuricemia 01/2016
1	Neoplasms (Cancer) 07/2012
1	Hyperinsulinism (Hyperinsulinemia) 07/2011
1	Stroke (Strokes) 12/2010
1	Dyslipidemias (Dyslipidemia) 01/2007
1	Insulin Resistance 01/2007

Drug/Important Bio-Agent (IBA)

12	Iohexol (Omnipaque)FDA Link 01/2022 - 12/2010
7	CreatinineIBA 07/2022 - 01/2007
4	AlbuminsIBA 12/2022 - 01/2007
4	Cystatin CIBA 01/2021 - 12/2010
4	Glucose (Dextrose)FDA LinkGeneric 01/2018 - 01/2007
3	HDL CholesterolIBA 08/2021 - 01/2007
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2007
2	Proteins (Proteins, Gene)FDA Link 07/2022 - 11/2020
2	Uric Acid (Urate)IBA 05/2017 - 05/2016
2	AdiponectinIBA 01/2017 - 01/2016
1	Orosomucoid (Seromucoid)IBA 12/2022
1	Tissue Inhibitor of Metalloproteinase-1IBA 01/2022
1	Matrix Metalloproteinase 2 (Gelatinase A)IBA 01/2022
1	Edetic Acid (EDTA)FDA Link 01/2021
1	Epidermal Growth Factor (EGF)IBA 01/2021
1	Syndecan-4IBA 11/2018
1	Syndecan-1 (Syndecan 1)IBA 11/2018
1	Triglycerides (Triacylglycerol)IBA 01/2018
1	Antihypertensive Agents (Antihypertensives)IBA 02/2017
1	Hexosaminidases (Hexosaminidase)IBA 02/2016
1	Lipoproteins (Lipoprotein)IBA 01/2007
1	Insulin (Novolin)FDA Link 01/2007

Therapy/Procedure

1	Conservative Treatment 01/2021
1	Therapeutics 01/2021
1	Kidney Transplantation 01/2021
1	Denervation 01/2021
1	Renal Replacement Therapy (Therapies, Renal Replacement) 01/2021